Seminars in Arthritis & Rheumatism (04/08/2015) Feldman, Steven R.

Regulatory agencies, professional associations, and healthcare providers have all published articles and guidelines about how biosimilars can be integrated into the clinical management of patients with inflammatory disorders. With the recent approval of the biosimilar infliximab in some countries, biosimilars have become a reality for providers of patients with these conditions. For successful integration of biosimilars into clinical practice, physicians must be familiar with such factors as variation in innovator/reference products, extrapolation of data, naming and labeling, interchangeability, and pharmacovigilance.

Web Link 

Abstract News © 2015 INFORMATION, INC.

New & Noteworthy